New drug targets tough cancer mutation in early trial

NCT ID NCT06227377

Recruiting now Disease control Sponsor: Quanta Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called QTX3034, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 250 participants will take part. Success could lead to better treatments for these hard-to-treat cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QTX3034 (a drug) and cetuximab (a combination drug)
What this could lead to: If this works, it could point toward a new treatment option for people with hard-to-treat cancers that have a specific KRAS mutation.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. It is small and may not lead to a proven treatment. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
SCRI- Nashville
RECRUITING

Nashville, Tennessee, 37203, United States
START San Antonio, LLC
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute (SCRI)
RECRUITING

Denver, Colorado, 80218, United States
Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
UCLA Hematology/Oncology
RECRUITING

Los Angeles, California, 90095, United States
University of Utah, Huntsman Cancer Center
RECRUITING

Salt Lake City, Utah, 84112, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.